Still, these positive results can be enhanced when in combination with other drugs, such as metformin, which allows for an effective treatment plan with no increase in adverse symptoms usually seen with the treatment of semaglutide alone [121, 122, 125, 126]
Combination with muscle-preserving agents: Companies developing myostatin and activin pathway inhibitors alongside GLP-1RAs are addressing a real unmet need that Novo Nordisk and Eli Lilly are also pursuing but have not yet solved
Last, we call upon clinicians, researchers, regulators, and industry stakeholders to address existing gaps in accessibility and explore opportunities for enhancing the use of GLP-1R agonists in both individualized care and broader public health contexts
11-357(a), 11-363(a), (c)
It just means asking yourself, Where is the protein here? before you eat
doi: 10.1111/dom.12639 84 ManigaultKRThurstonMM